- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
Sandoz Group
Market Cap: CHF 23.7b
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
SDZ
CHF 54.98
7D
10.6%
1Y
37.7%
Galderma Group
Market Cap: CHF 36.4b
Operates as a dermatology company worldwide.
GALD
CHF 153.30
7D
7.3%
1Y
85.1%
PolyPeptide Group
Market Cap: CHF 809.9m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 24.55
7D
-1.8%
1Y
-23.6%